Amylyx Pharmaceuticals, Inc. (AMLX) Financials

AMLX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 293.6 million 20.4 million
Dec. 31, 2025 332.6 million 27.4 million
Sept. 30, 2025 362.7 million 30.7 million
June 30, 2025 194.6 million 26.7 million

AMLX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -36.9 million ?
Dec. 31, 2025 -28.0 million 6.4 million
Sept. 30, 2025 -30.4 million 7.1 million
June 30, 2025 -25.3 million 7.4 million

AMLX Net Income

No data available :(

AMLX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 279.8 million 4.5 million -
Dec. 31, 2025 317.0 million 4.7 million 6.0 million
Sept. 30, 2025 344.0 million - 5.0 million
June 30, 2025 180.8 million - 6.0 million

AMLX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 110.6 million
Dec. 31, 2025 94.6 million
Sept. 30, 2025 93.3 million
June 30, 2025 89.1 million

AMLX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 27.6 million 16.2 million -
Dec. 31, 2025 86000 21.1 million 15.4 million -
Sept. 30, 2025 24000 19.9 million 16.2 million -
June 30, 2025 17000 27.1 million 15.6 million -

AMLX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 98000
Dec. 31, 2025 - 108000
Sept. 30, 2025 - 19.9 million
June 30, 2025 - 141000

AMLX

Price: $13.91

52 week price:
4.76
18.61

Earnings Per Share: -1.48 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 390250

Market Capitalization: 1.1 billion

Links: